Zhenxing Research Institute, July 20 Huitianfu Fund Zheng Lei's fund announced the report, the synthesis of its funds' financial results, the proportion of Hong Kong stocks has increased significantly, Kang Fang Bio-B, Fosun Pharmaceuticals and so on have been increased. Li Ning, Hagia Medical, Kanglong Huacheng and other newly entered the top ten positions. In addition, individual stocks in the medical device industry have attracted more attention. Compared with the last quarter, Fosun Pharmaceuticals and other companies have increased their holdings, while Opcom, Emick and East Fulong have newly entered the top 10 positions; the pharmaceutical industry sector has been reduced, Zhifei biology, Changchun Hi-tech, Hengrui Pharmaceuticals, etc. have withdrawn from the top ten positions, while Yao Ming Kant and Kellein have been reduced. At present, its fund comprehensive position of the top three stocks are Yao Ming Kant, Mindray Medical, Ayre Ophthalmology. The changes in the heavy positions of the Fund are as follows:
Mr. Zheng Lei: a well-known fund manager of Huitianfu Fund, the top 50 of the Securities Star list in 2020. After working for 5 years and 301 days, the total assets of the current fund are 30.757 billion yuan, and the cumulative income of Huitianfu innovative medicine mixed with its management is as high as 226.29%.
Founded in 2005, Huitianfu Fund manages a total of 325 funds, with 50 fund managers and a total management scale of 929.939 billion yuan. Its best-performing fund product in the past year is Huitianfu Zhong Zheng New Energy vehicle A, with a new unit net worth of 2.92, an increase of 114.05% in the past year. Its latest product is Huidianfu medium and high grade credit debt A, the type is bond-long debt, and the centralized subscription period is from 2021-06-28 to 2021-07-30.
The above data are derived from the public data of fund companies and calculated by the Securities Star data Center. more details can be found in [Zhenxing Research Institute].